Grown Rogue International (GRUSF) Income from Non-Controlling Interests (2013 - 2026)
Grown Rogue International's (GRUSF) quarterly Income from Non-Controlling Interests came in at -$488826.0 in Q1 2026, down 239.26% year-on-year from $351029.0 in Q1 2025, and up 100.0% quarter-over-quarter from -$321.7 billion in Q4 2025.
Grown Rogue International (GRUSF) Income from Non-Controlling Interests (2013 - 2026) Analysis & Trends
Grown Rogue International's Income from Non-Controlling Interests history runs 11 years deep, the most recent figure standing at -$488826.0 for Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 239.26% year-over-year to -$488826.0 in Q1 2026; TTM through Mar 2026 was -$182.1 billion, a 29.91% decrease from a year earlier, with the FY2025 full-year figure at -$1.5 million, down 8499.04% from the prior year.
- Income from Non-Controlling Interests rose to -$488826.0 in Q1 2026 per GRUSF's latest filing, from -$321.7 billion in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $139.6 billion in Q3 2025 and bottomed at -$321.7 billion in Q4 2025.
- The 5-year median for Income from Non-Controlling Interests is $30728.0 (2024), against an average of -$21.5 billion.
- Across the five-year window, Income from Non-Controlling Interests surged 11432.01% in 2022 and plunged 915246434.11% in 2024, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $564607.0 in 2022, then tumbled by 94.76% to $29607.0 in 2023, then plunged by 915246434.11% to -$271.0 billion in 2024, then retreated by 18.72% to -$321.7 billion in 2025, then jumped by 100.0% to -$488826.0 in 2026.
- Per Business Quant, the three latest GRUSF Income from Non-Controlling Interests figures stand at -$488826.0 (Q1 2026), -$321.7 billion (Q4 2025), and $139.6 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.67 Bn | 30.73 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.69 Bn | 23.63 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.12 Bn | 20.97 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.24 Bn | 18.44 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.83 Bn | 16.51 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.22 Bn | 785.00 Mn | - |
| 10 | Grown Rogue International | 99.97 Mn | 86.26 Mn | 3.96 Mn | -488,826.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -488,826.00 |
| Dec 31, 2025 | -321.70 Bn |
| Sep 30, 2025 | 139.57 Bn |
| Jun 30, 2025 | 99,131.00 |
| Mar 31, 2025 | -144,088.00 |
| Dec 31, 2024 | -270.98 Bn |
| Sep 30, 2024 | 130.78 Bn |
| Jun 30, 2024 | 80,039.42 |
| Mar 31, 2024 | 30,728.00 |
| Dec 31, 2023 | 29,607.00 |
| Oct 31, 2023 | 210,129.00 |
| Jul 31, 2023 | 119,093.00 |
| Apr 30, 2023 | -867.00 |
| Jan 31, 2023 | -339,408.00 |
| Jan 31, 2022 | 564,607.00 |
| Oct 31, 2021 | 1.12 Mn |
| Jul 31, 2021 | 283,126.00 |
| Apr 30, 2021 | -15,306.00 |
| Jan 31, 2021 | 4,896.00 |
| Oct 31, 2020 | -38,608.00 |